ARTICLE | Clinical News

Dymista azelastine/fluticasone: Phase III data

June 27, 2011 7:00 AM UTC

A post hoc analysis of the double-blind, placebo- and active-controlled, U.S. Phase III MP4001 trial showed that 49.1% of patients treated with Dymista achieved a 50% improvement in 12-hour reflective TNSS from baseline to week 2. Additionally, time to reach a 50% improvement in reflective TNSS was 5-6 days faster for Dymista compared to the active comparators azelastine or fluticasone propionate alone. Data were presented at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. ...